RESPIRATORY PANEL COMBINED I

Respiratory Panel Combined I is an advanced multiplex molecular diagnostic test designed to detect multiple respiratory pathogens from a single patient sample. Using highly sensitive PCR technology, the panel simultaneously identifies a wide range of respiratory viruses and bacteria responsible for upper and lower respiratory tract infections, enabling rapid and accurate diagnosis.

Respiratory infections can present with symptoms such as fever, cough, sore throat, nasal congestion, breathing difficulty, wheezing, chest pain, and pneumonia. Since many respiratory pathogens produce similar clinical symptoms, comprehensive testing helps healthcare providers identify the exact cause of illness and select appropriate treatment strategies.

Benefits of the Test

• Simultaneously detects multiple respiratory pathogens.
• Provides rapid and highly accurate molecular diagnosis.
• Identifies viral and bacterial causes of respiratory illness.
• Supports targeted treatment decisions.
• Reduces unnecessary antibiotic use.
• Assists in diagnosing pneumonia and severe respiratory infections.
• Supports infection control and outbreak management.
• Improves patient outcomes through early diagnosis.

Why Doctors Recommend This Test

Doctors recommend this test for patients with acute respiratory symptoms, suspected pneumonia, severe flu-like illness, unexplained respiratory infections, hospitalization due to respiratory disease, or when rapid pathogen identification is clinically important. The test is especially valuable for children, elderly individuals, immunocompromised patients, and those with chronic respiratory conditions.

Accurate identification of respiratory pathogens helps clinicians optimize treatment plans and improve overall patient management.

Preparation Before Test

• No fasting is required.
• Nasopharyngeal swabs, throat swabs, sputum, or respiratory secretions may be collected.
• Inform your doctor about recent medications or treatments.
• Follow all instructions provided by healthcare professionals.
• Provide relevant medical history and symptom details.
• Ensure prompt sample collection and transportation to the laboratory.

Normal Reporting Time

Most Respiratory Panel Combined I reports at Focus Diagnostics are available within 2–3 hours after sample processing. Additional quality verification procedures may occasionally require extra time depending on laboratory protocols.

Who Should Take This Test?

This test may be recommended for:

• Patients with acute respiratory tract infections.
• Individuals with fever, cough, and breathing difficulties.
• People with suspected viral or bacterial pneumonia.
• Hospitalized patients with respiratory symptoms.
• Children and elderly individuals.
• Immunocompromised patients.
• Patients with recurrent respiratory infections.
• Individuals requiring comprehensive respiratory pathogen screening.

Detailed Information

Respiratory infections are among the most common causes of illness worldwide and can affect individuals of all ages. These infections may involve the upper respiratory tract, including the nose, throat, and sinuses, or the lower respiratory tract, including the bronchi and lungs. Because symptoms often overlap among different infections, identifying the responsible pathogen based solely on clinical presentation can be challenging.

Respiratory Panel Combined I uses advanced multiplex Polymerase Chain Reaction (PCR) technology to detect genetic material from multiple respiratory pathogens simultaneously. This approach provides significantly greater sensitivity and faster results compared to traditional culture-based methods and allows comprehensive pathogen identification from a single specimen.

The panel may detect a broad range of respiratory viruses and bacterial pathogens commonly associated with respiratory illness. Depending on the panel configuration, organisms identified may include Influenza A and B viruses, Respiratory Syncytial Virus (RSV), Human Metapneumovirus, Adenovirus, Rhinovirus, Enterovirus, Parainfluenza viruses, seasonal Coronaviruses, Mycoplasma pneumoniae, Chlamydia pneumoniae, Bordetella pertussis, and other clinically significant respiratory pathogens.

Rapid pathogen identification helps clinicians distinguish between viral and bacterial infections, enabling evidence-based treatment decisions and reducing unnecessary antibiotic exposure. Early diagnosis is particularly important for vulnerable populations such as infants, elderly individuals, cancer patients, transplant recipients, and those with chronic respiratory diseases.

The test is also valuable during seasonal influenza outbreaks, community-acquired pneumonia investigations, hospital infection control programs, and emergency department evaluations. Comprehensive respiratory pathogen detection supports improved patient care and infection prevention strategies.

Because multiple pathogens can cause similar respiratory symptoms, multiplex respiratory testing provides a more efficient diagnostic approach than performing numerous individual tests. Results should always be interpreted alongside clinical findings, imaging studies, and other laboratory investigations.

At Focus Diagnostics, Respiratory Panel Combined I testing is performed using advanced molecular diagnostic platforms, highly sensitive multiplex PCR technology, and stringent quality assurance protocols to provide accurate, reliable, and clinically meaningful diagnostic results.